WO2006120474A3 - Compositions for inducing an immune response against tumor antigens - Google Patents

Compositions for inducing an immune response against tumor antigens Download PDF

Info

Publication number
WO2006120474A3
WO2006120474A3 PCT/GB2006/001774 GB2006001774W WO2006120474A3 WO 2006120474 A3 WO2006120474 A3 WO 2006120474A3 GB 2006001774 W GB2006001774 W GB 2006001774W WO 2006120474 A3 WO2006120474 A3 WO 2006120474A3
Authority
WO
WIPO (PCT)
Prior art keywords
inducing
compositions
immune response
antigen
response against
Prior art date
Application number
PCT/GB2006/001774
Other languages
French (fr)
Other versions
WO2006120474A2 (en
Inventor
Richard Anderson
Martin Cripps
Gill Pearce
Original Assignee
Oxxon Therapeutics Ltd
Richard Anderson
Martin Cripps
Gill Pearce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0515658A external-priority patent/GB0515658D0/en
Application filed by Oxxon Therapeutics Ltd, Richard Anderson, Martin Cripps, Gill Pearce filed Critical Oxxon Therapeutics Ltd
Priority to EP06727116A priority Critical patent/EP1890724A2/en
Publication of WO2006120474A2 publication Critical patent/WO2006120474A2/en
Publication of WO2006120474A3 publication Critical patent/WO2006120474A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Priming and boosting compositions and methods for inducing an immune response, e.g. a CD8+ T cell response, to an antigen e.g. a tumour antigen, for example a melanoma antigen. Methods of treating metastasis of melanoma in mammals. DNA plasmids and/or poxvirus, e.g. modified vaccinia virus Ankara, as priming and/or boosting compositions for inducing immune responses to antigen epitopes.
PCT/GB2006/001774 2005-05-13 2006-05-15 Compositions for inducing an immune response against tumor antigens WO2006120474A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06727116A EP1890724A2 (en) 2005-05-13 2006-05-15 Compositions for inducing an immune response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68083805P 2005-05-13 2005-05-13
US60/680,838 2005-05-13
GB0515658.3 2005-07-29
GB0515658A GB0515658D0 (en) 2005-05-13 2005-07-29 Compositions for inducing an immune response

Publications (2)

Publication Number Publication Date
WO2006120474A2 WO2006120474A2 (en) 2006-11-16
WO2006120474A3 true WO2006120474A3 (en) 2007-02-22

Family

ID=37124745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001774 WO2006120474A2 (en) 2005-05-13 2006-05-15 Compositions for inducing an immune response against tumor antigens

Country Status (2)

Country Link
EP (1) EP1890724A2 (en)
WO (1) WO2006120474A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US20080199485A1 (en) 2007-02-15 2008-08-21 Mannkind Corporation Method for enhancing T cell response
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
JP5690814B2 (en) * 2009-04-28 2015-03-25 ザ・ジョンズ・ホプキンス・ユニバーシティー Compositions and methods for enhancing antigen-specific immune responses
EP2490713A2 (en) * 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CN115300622A (en) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 Use of inactivated modified vaccinia virus ankara as a sole immunotherapy of solid tumors or in combination with immune checkpoint blockers
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
JP7025339B2 (en) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター Replicable attenuated vaccinia virus with or without expression of human FLT3L or GM-CSF with thymidine kinase deletion for cancer immunotherapy
SG11201807022XA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
EP3706768A4 (en) * 2017-11-06 2021-08-25 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
GB201812647D0 (en) * 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056919A2 (en) * 1997-06-09 1998-12-17 Oxxon Pharmaccines Limited Methods and reagents for vaccination which generate a cd8 t cell immune response
WO2002024224A2 (en) * 2000-09-21 2002-03-28 Oxxon Pharmaccines Limited Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
WO2005026370A2 (en) * 2003-09-05 2005-03-24 Sanofi Pasteur Limted. Multi-antigen vectors for melanoma
WO2006061643A1 (en) * 2004-12-09 2006-06-15 Oxxon Therapeutics Limited Method for vaccinating usign a prime-boost regime and hsv as a vector

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056919A2 (en) * 1997-06-09 1998-12-17 Oxxon Pharmaccines Limited Methods and reagents for vaccination which generate a cd8 t cell immune response
WO2002024224A2 (en) * 2000-09-21 2002-03-28 Oxxon Pharmaccines Limited Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
WO2005026370A2 (en) * 2003-09-05 2005-03-24 Sanofi Pasteur Limted. Multi-antigen vectors for melanoma
WO2006061643A1 (en) * 2004-12-09 2006-06-15 Oxxon Therapeutics Limited Method for vaccinating usign a prime-boost regime and hsv as a vector

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
LINDSEY K R ET AL: "Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma", CLINICAL CANCER RESEARCH 15 APR 2006 UNITED STATES, vol. 12, no. 8, 15 April 2006 (2006-04-15), pages 2526 - 2537, XP002410671, ISSN: 1078-0432 *
MARSHALL JOHN L ET AL: "Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses", JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 23, 1 December 2000 (2000-12-01), pages 3964 - 3973, XP002410670, ISSN: 0732-183X *
MCSHANE HELEN ET AL: "Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 69, no. 2, February 2001 (2001-02-01), pages 681 - 686, XP002192945, ISSN: 0019-9567 *
ROSENBERG STEVEN A ET AL: "Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 AUG 2003, vol. 9, no. 8, 1 August 2003 (2003-08-01), pages 2973 - 2980, XP002410669, ISSN: 1078-0432 *
SCHNEIDER J ET AL: "ENHANCED IMMUNOGENICITY FOR CD8+ T CELL INDUCTION AND COMPLETE PROTECTIVE EFFICACY OF MALARIA DNA VACCINATION BY BOOSTING WITH MODIEFIED VACCINIA VIRUS ANKARA", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 4, no. 4, April 1998 (1998-04-01), pages 397 - 402, XP000739989, ISSN: 1078-8956 *
TAGAWA S T ET AL: "Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 98, no. 1, 1 July 2003 (2003-07-01), pages 144 - 154, XP002359066, ISSN: 0008-543X *
VAN BAREN NICOLAS ET AL: "Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 10 DEC 2005, vol. 23, no. 35, 10 December 2005 (2005-12-10), pages 9008 - 9021, XP009075846, ISSN: 0732-183X *
WANG X ET AL: "Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 19-20, 2 June 2003 (2003-06-02), pages 2288 - 2297, XP004424136, ISSN: 0264-410X *
ZAJAC P ET AL: "Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 14, no. 16, 1 November 2003 (2003-11-01), pages 1497 - 1510, XP002322835, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
WO2006120474A2 (en) 2006-11-16
EP1890724A2 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
WO2006120474A3 (en) Compositions for inducing an immune response against tumor antigens
EP2385059A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2009015842A3 (en) Novel immunogenic epitopes for immunotherapy
MX349096B (en) Anti-pd-l1 antibodies and uses thereof.
ATE494303T1 (en) TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND ASSOCIATED CANCER VACCINE
WO2006020889A3 (en) Dendritic cell vaccines for treating cancer made from embryonic stem cells
WO2014009438A3 (en) Mycobacterial antigen vaccine
UA118340C2 (en) Pr13.5 promoter for robust t-cell and antibody responses
CA2817709C (en) Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
AR080585A1 (en) VACCINATION AGAINST TUMORS UNDERSTANDING AN IMMUNE HUMORAL RESPONSE AGAINST OWN PROTEINS
WO2009117656A3 (en) Capsid-incorporated antigen for novel adenovirus vaccine
WO2006081323A3 (en) Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
WO2009048839A3 (en) Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
WO2007130555A3 (en) Augmentation of immune response to cancer vaccine
WO2008080091A3 (en) Activation of rig-i pathway
EA200900738A1 (en) SLIP PROTEINS CONTAINING ANTIGENS OF TUMOR TENSIONS NY-ESO-1 AND LAGE-1
EA200701440A1 (en) COMPOSITIONS FOR IMMUNIZATION AGAINST MYCOBACTERIA
MX2022004086A (en) Anti-tigit antibodies and uses thereof.
Maertzdorf et al. Molecular signatures for vaccine development
WO2009026456A3 (en) Poxvirus methods and compositions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006727116

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06727116

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006727116

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2006727116

Country of ref document: EP